Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2016 1
2017 2
2018 7
2019 5
2020 1
2021 5
2022 5
2023 2
2024 3
2025 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial.
Chen J, Jiang F, Zhao C, Chai J, Li L, Guan Q, Li X, Wang F, Li A, Gao H, Wang M, Fu L, Nie F, Ling W, Deng H, Zhou L. Chen J, et al. Hum Vaccin Immunother. 2023 Aug 1;19(2):2245721. doi: 10.1080/21645515.2023.2245721. Hum Vaccin Immunother. 2023. PMID: 37587615 Free PMC article. Clinical Trial.
The quadrivalent inactivated split-virion influenza vaccine is effective against four influenza virus phenotypes. In this trial, the immunogenicity and safety of the quadrivalent inactivated split-virion influenza …
The quadrivalent inactivated split-virion influenza vaccine is effective against four influenza vi …
Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial.
Huang X, Fan T, Li L, Nian X, Zhang J, Gao X, Zhao W, Chen W, Zhang Z, Yao Z, Han X, Shi J, Wang Y, Bian H, Shi N, Li X, Duan K, Li G, Yang X. Huang X, et al. Hum Vaccin Immunother. 2022 Nov 30;18(5):2079924. doi: 10.1080/21645515.2022.2079924. Epub 2022 Jun 17. Hum Vaccin Immunother. 2022. PMID: 35714276 Free PMC article. Clinical Trial.
BACKGROUND: A quadrivalent split influenza vaccine IIV4-W against both influenza A and B viruses is urgently needed. ...All these AEs were mild and self-limiting, and no serious AEs related to the vaccines were observed. IIV4-W elicited a …
BACKGROUND: A quadrivalent split influenza vaccine IIV4-W against both influenza A and B viruses is urgen …
Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults 60 years of age: Results from a phase III, randomized clinical trial.
Sanchez L, Nakama T, Nagai H, Matsuoka O, Inoue S, Inoue T, Shrestha A, Pandey A, Chang LJ, De Bruijn I; QHD00010 Study Group. Sanchez L, et al. Vaccine. 2023 Apr 6;41(15):2553-2561. doi: 10.1016/j.vaccine.2023.02.071. Epub 2023 Mar 10. Vaccine. 2023. PMID: 36906404 Free article. Clinical Trial.
BACKGROUND: A high-dose, split-virion inactivated quadrivalent influenza vaccine (IIV4-HD; Sanofi) is being used for the prevention of influenza in multiple countries. This study examined the immunogenicity and safety of the IIV4-H …
BACKGROUND: A high-dose, split-virion inactivated quadrivalent influenza vaccine (IIV4-HD; Sanofi) is bei …
Immunogenicity and safety of an egg culture-based quadrivalent inactivated non-adjuvanted subunit influenza vaccine in subjects 3 years: A randomized, multicenter, double-blind, active-controlled phase III, non-inferiority trial.
Zhang Y, Wang Y, Jia C, Li G, Zhang W, Li Q, Chen X, Leng W, Huang L, Xie Z, Zhang H, You W, An R, Jiang H, Zhao X, Cheng S, Tan J, Cui W, Gao F, Lu W, Wang Y, Yang Y, Xia S, Wang S. Zhang Y, et al. Vaccine. 2022 Aug 12;40(34):4933-4941. doi: 10.1016/j.vaccine.2022.06.078. Epub 2022 Jul 7. Vaccine. 2022. PMID: 35810063 Clinical Trial.
Subunit influenza vaccine only formulated with surface antigen proteins has better safety profiles relative to split-virion influenza vaccine. Compared to the traditional quadrivalent split-virion influenza vaccine, a …
Subunit influenza vaccine only formulated with surface antigen proteins has better safety profiles relative to split-vi …
Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial.
Chen H, Huang Z, Chang S, Hu M, Lu Q, Zhang Y, Wang H, Xiao Y, Wang H, Ge Y, Zou Y, Cui F, Han S, Zhang M, Wang S, Zhu X, Zhang B, Li Z, Ren J, Chen X, Ma R, Zhang L, Guo X, Luo L, Sun X, Yang X. Chen H, et al. Vaccine. 2022 Aug 26;40(36):5322-5332. doi: 10.1016/j.vaccine.2022.07.033. Epub 2022 Jul 29. Vaccine. 2022. PMID: 35931636 Free PMC article. Clinical Trial.
BACKGROUND: The safety and immunogenicity of the coadministration of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV), quadrivalent split-virion inactivated influenza vaccine (IIV4), and 23-valent pneumococcal polysaccharid …
BACKGROUND: The safety and immunogenicity of the coadministration of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV), …
Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion inactivated influenza vaccine in healthy population aged 9-59 years: A randomized, double-blind, controlled, phase IV clinical trial.
Gao Y, Yang X, Li X, Chen H, Li Y, Tan X, Yu D, Feng T, Zhou S, Lei S, Zhao C, Wang J, Guan Q. Gao Y, et al. Vaccine. 2024 Aug 30;42(21):126182. doi: 10.1016/j.vaccine.2024.126182. Epub 2024 Aug 6. Vaccine. 2024. PMID: 39116486 Free article. Clinical Trial.
OBJECTIVES: This study was to assess the lot-to-lot consistency, immunogenicity and safety of three manufacturing lots of a quadrivalent inactivated influenza vaccine (IIV4). METHODS: A randomized, double-blind, phase IV clinical trial was conducted in …
OBJECTIVES: This study was to assess the lot-to-lot consistency, immunogenicity and safety of three manufacturing lots of a quadrivalent …
Immunogenicity and safety of concomitant administration of recombinant COVID-19 vaccine and quadrivalent inactivated influenza vaccine in Chinese adults: An open-label, randomized, controlled trial.
Huang T, Yu J, Zhang S, Teng D, Dai D, Zhu Y, Gao L. Huang T, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2330770. doi: 10.1080/21645515.2024.2330770. Epub 2024 Apr 11. Hum Vaccin Immunother. 2024. PMID: 38602539 Free PMC article. Clinical Trial.
The immunogenicity and safety of the concomitant administration of recombinant COVID-19 vaccine and quadrivalent inactivated influenza vaccine (Split Virion) (QIIV) in Chinese adults are unclear. ...Eligible healthy adults were randomly a …
The immunogenicity and safety of the concomitant administration of recombinant COVID-19 vaccine and quadrivalent inactivate …
Safety and immunogenicity of a quadrivalent inactivated subunit non-adjuvanted influenza vaccine: A randomized, double-blind, active-controlled phase 1 clinical trial.
Wang Y, Zhang Y, Wu H, Huang L, Yu H, Xie Z, Zhang H, Zhang W, Chen X, Zhang H, Zhang H, Jia C, Xia S, Wang S. Wang Y, et al. Vaccine. 2021 Jun 29;39(29):3871-3878. doi: 10.1016/j.vaccine.2021.05.070. Epub 2021 Jun 1. Vaccine. 2021. PMID: 34088505 Free article. Clinical Trial.
Quadrivalent influenza inactivated vaccine (IIV4) is more likely to provide wider protection against yearly circulating influenza viruses than trivalent inactivated influenza vaccine (IIV3). ...As a result, the FD-subunit NA …
Quadrivalent influenza inactivated vaccine (IIV4) is more likely to provide wider protection against yearly circ …
Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults.
Claeys C, Drame M, García-Sicilia J, Zaman K, Carmona A, Tran PM, Miranda M, Martinón-Torres F, Thollot F, Horn M, Schwarz TF, Behre U, Merino JM, Sadowska-Krawczenko I, Szymański H, Schu P, Neumeier E, Li P, Jain VK, Innis BL. Claeys C, et al. BMC Infect Dis. 2018 Apr 18;18(1):186. doi: 10.1186/s12879-018-3079-8. BMC Infect Dis. 2018. PMID: 29669531 Free PMC article. Clinical Trial.
BACKGROUND: GSK has modified the licensed monovalent bulk manufacturing process for its split-virion inactivated quadrivalent influenza vaccine (IIV4) to harmonize the process among different strains, resulting in an increased number of finished …
BACKGROUND: GSK has modified the licensed monovalent bulk manufacturing process for its split-virion inactivated quadrivale …
Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study.
Fan R, Huang X, Nian X, Ou Z, Zhou J, Zhang J, Zeng P, Zhao W, Deng J, Chen W, Chen S, Duan K, Chen Y, Li X, Zhang J, Yang X. Fan R, et al. Hum Vaccin Immunother. 2022 Dec 31;18(1):1-9. doi: 10.1080/21645515.2021.1967041. Epub 2021 Sep 2. Hum Vaccin Immunother. 2022. PMID: 34473607 Free PMC article. Clinical Trial.
To control seasonal influenza epidemics in elders, a quadrivalent, inactivated, split-virion influenza vaccine (IIV4) comprising A and B lineages is produced for young individuals and adults aged 60 years. In this phase III, rando …
To control seasonal influenza epidemics in elders, a quadrivalent, inactivated, split-virion influenza …
27 results